Three new distributor agreements build on initial China sales and extend the Company’s distributor-led commercial strategy.
LONDON, 29 October, 2026 /PRNewswire/ – Virax Biolabs Group Limited (NASDAQ: VRAX) (“Virax” or the “Company”) today announced that, through its China subsidiary, Shanghai Xitu Consulting Co., Ltd., it has entered into non-exclusive distribution agreements with AmyJet Scientific Inc., Jiangsu Real-Gen Biotechnology Co., Ltd., and Zhixi (Shanghai) Biotechnology Co., Ltd. for its ImmuneSelect research-use immune profiling products.
KEY HIGHLIGHTS:
- Three non-exclusive appointments create distribution routes to specified research customers across six mainland Chinese markets, including major biotech centres in Beijing, Shanghai, Suzhou and Wuhan.
- AmyJet, which reports more than 200 international life sciences supplier relationships and already offers ELISpot and other immunology research reagents, will target industrial and biotechnology customers in Beijing, Shanghai and Hubei.
- Jiangsu Real-Gen, with a regional presence in Suzhou, Nanjing, Hefei and Jinan, will target academic, biopharmaceutical and other research customers in Jiangsu, Anhui and Shandong.
- Zhixi adds a targeted Shanghai academic sales channel, supported by the research-reagent trading experience of its common ownership with Shanghai KEL Biotech.
- The initial product focus is ELISpot assay plates and antigen-specific peptide pools for infectious disease, vaccine and cellular immunity research.
- Local distribution supports commercial expansion while limiting the need to build a larger direct sales organisation.
